Table 2 Clinical treatment response of patients with or without nimotuzumab before and after matching.
Prognosis | Overall | Before matching | After matching | ||||
|---|---|---|---|---|---|---|---|
Nimotuzumab | No- Nimotuzumab | P value | Nimotuzumab | No- Nimotuzumab | P value | ||
Treatment response | 0.001 | 0.003 | |||||
CR | 67 (34.4%) | 31 (51.7%) | 36(26.7%) | 28(551.9%) | 12(22.2%) | ||
PR | 110 (56.4%) | 28 (46.7%) | 82 (60.7%) | 25(46.3%) | 36(66.7%) | ||
SD | 18 (9.2%) | 1(1.7%) | 17(12.6%) | 1(1.9%) | 6(11.1%) | ||
CR response | 0.001 | 0.001 | |||||
CR | 67 (34.4%) | 31 (51.7%) | 36 (26.7%) | 28(51.9%) | 12(22.1%) | ||
Non-CR | 128 (65.6%) | 29 (48.3%) | 99 (73.3%) | 26(48.1%) | 42(77.8%) | ||
Binary response | 0.015 | 0.003 | |||||
CR + PR | 177 (90.8%) | 59 (98.3%) | 118 (87.4%) | 53(98.1%) | 48(88.9%) | ||
SD | 18 (9.2%) | 1 (1.7%) | 17 (12.6%) | 1(1.9%) | 6(11.1%) | ||
2-year PFS rate | 89.5% | 89.1% | 89.4% | 0.971 | 87.5% | 94.4% | 0.406 |
2-year OS rate | 92.5% | 92.7% | 92.5% | 0.836 | 91.6% | 94.4% | 0.927 |
